Valuation: Sanofi

Market Cap 93.78B 109B 87.88B 80.27B 151B 10,434B 153B 1,037B 404B 5,264B 411B 402B 17,433B P/E 2026 *
12.5x
P/E 2027 * 10.9x
Enterprise Value 105B 123B 98.61B 90.08B 170B 11,709B 172B 1,163B 453B 5,907B 461B 451B 19,563B EV / Sales 2026 *
2.21x
EV / Sales 2027 * 2.01x
Free-Float
88.34%
Yield 2026 *
5.43%
Yield 2027 * 5.75%
1 week+2.62%
Current month+4.81%
1 month+3.16%
3 months+3.16%
6 months-2.49%
Current year-3.92%
1 week 38.2
Extreme 38.2
39.4
1 month 36.2
Extreme 36.2
40
3 years 35.6
Extreme 35.6
55
5 years 35.6
Extreme 35.6
55
10 years 30.6
Extreme 30.6
55
Manager TitleAgeSince
Chief Executive Officer 65 01/05/2026
Director of Finance/CFO 64 01/04/2024
Chief Tech/Sci/R&D Officer 51 11/09/2023
Director TitleAgeSince
Director/Board Member 60 30/04/2019
Director/Board Member 57 28/04/2020
Director/Board Member 65 28/04/2020
Change 5-day change 1-year change 3-year change Capi.($)
+0.51%+2.62%-9.68%-19.34% 109B
-1.06%+0.65%+77.42%+122.82% 1,111B
+0.53%+0.75%+53.10%+64.29% 658B
+0.48%+2.65%+28.06%+81.19% 467B
+0.92%+4.97%+42.94%+43.69% 369B
+1.25%+4.00%+25.87%+42.82% 301B
+3.02%+7.92%+4.24%+16.06% 256B
-0.36%+3.99%+53.31%+72.49% 240B
+2.86%+5.27%-15.42%-52.34% 207B
+1.38%+3.72%+30.33%+93.56% 182B
Average +1.05%+4.49%+29.02%+46.52% 421.22B
Weighted average by Cap. +0.61%+4.68%+44.32%+69.57%

Financials

2026 *2027 *
Net sales 47.59B 55.54B 44.6B 40.74B 76.88B 5,295B 77.63B 526B 205B 2,671B 209B 204B 8,847B 50.7B 59.16B 47.5B 43.39B 81.89B 5,640B 82.7B 560B 218B 2,846B 222B 217B 9,424B
Net income 7.91B 9.23B 7.41B 6.77B 12.78B 880B 12.9B 87.44B 34.04B 444B 34.66B 33.91B 1,471B 9.24B 10.79B 8.66B 7.91B 14.93B 1,028B 15.08B 102B 39.77B 519B 40.5B 39.62B 1,718B
Net Debt 11.46B 13.37B 10.74B 9.81B 18.51B 1,275B 18.69B 127B 49.3B 643B 50.2B 49.11B 2,130B 8.3B 9.69B 7.78B 7.11B 13.41B 924B 13.55B 91.78B 35.73B 466B 36.39B 35.59B 1,544B
Logo Sanofi
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).
Employees
-
Date Price Change
25/08/26 39.40 +0.51%
24/08/26 €39.20 0.00%
21/08/26 €39.20 +1.55%
20/08/26 €38.60 -1.03%
19/08/26 €39.00 +0.52%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
78.74EUR
Average target price
94.28EUR
Spread / Average Target
+19.73%

Quarterly revenue - Rate of surprise